AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patiens with recent ACS and low HDL-c.
The phase 3 BETonMACE trial did not meet the primary endpoint, a reduction in MACE with apabetalone, in high CV risk patients.
Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.
Epigenetic processes are involved in renal damage. Marta Ruiz-Ortega describes the role of vascular calcification and alkaline phosphatase (ALP) in CKD and effects of BET inhibition on vascular calcification.
ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.
BET proteins can stimulate inflammatory processes by regulating genes. Prof. Kausik Ray discusses the role of BET inhibition in reducing CVD risk in patients with diabetes.
Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.
In 48 patients with chronic kidney disease and coronary artery disease, apabetalone had beneficial effects on alkaline phosphatase levels and estimated glomerular filtration rate.